ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 283 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q4 2022. The put-call ratio across all filers is 0.89 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $697,089 | -26.2% | 25,943 | -2.1% | 0.00% | -33.3% |
| Q2 2023 | $944,847 | +42.7% | 26,496 | +1.6% | 0.00% | +50.0% |
| Q1 2023 | $662,127 | -45.8% | 26,068 | -13.5% | 0.00% | -50.0% |
| Q4 2022 | $1,222,681 | +33.3% | 30,145 | +8.7% | 0.00% | 0.0% |
| Q3 2022 | $917,000 | -4.7% | 27,721 | +1.4% | 0.00% | +33.3% |
| Q2 2022 | $962,000 | -48.6% | 27,337 | -32.8% | 0.00% | -25.0% |
| Q1 2022 | $1,870,000 | -42.3% | 40,658 | -16.8% | 0.00% | -33.3% |
| Q4 2021 | $3,241,000 | +15.5% | 48,894 | +8.8% | 0.01% | -25.0% |
| Q3 2021 | $2,805,000 | -35.9% | 44,923 | -15.0% | 0.01% | -38.5% |
| Q2 2021 | $4,378,000 | +32.7% | 52,861 | +6.3% | 0.01% | +30.0% |
| Q1 2021 | $3,298,000 | -6.9% | 49,731 | +7.8% | 0.01% | -23.1% |
| Q4 2020 | $3,541,000 | +130.4% | 46,143 | +29.3% | 0.01% | +85.7% |
| Q3 2020 | $1,537,000 | -2.8% | 35,692 | -2.6% | 0.01% | -12.5% |
| Q2 2020 | $1,582,000 | +142.3% | 36,639 | +61.3% | 0.01% | +60.0% |
| Q1 2020 | $653,000 | -75.4% | 22,710 | -45.7% | 0.01% | -58.3% |
| Q4 2019 | $2,654,000 | +142.4% | 41,835 | +7.7% | 0.01% | +100.0% |
| Q3 2019 | $1,095,000 | +2.5% | 38,844 | -3.6% | 0.01% | 0.0% |
| Q2 2019 | $1,068,000 | +38.0% | 40,313 | -4.4% | 0.01% | +20.0% |
| Q1 2019 | $774,000 | +59.9% | 42,188 | +8.2% | 0.01% | +66.7% |
| Q4 2018 | $484,000 | -45.7% | 39,005 | -16.2% | 0.00% | -50.0% |
| Q3 2018 | $892,000 | +35.8% | 46,542 | -3.6% | 0.01% | +50.0% |
| Q2 2018 | $657,000 | +127.3% | 48,273 | +20.3% | 0.00% | +100.0% |
| Q1 2018 | $289,000 | +95.3% | 40,127 | -0.4% | 0.00% | +100.0% |
| Q4 2017 | $148,000 | -18.7% | 40,282 | -4.4% | 0.00% | -50.0% |
| Q3 2017 | $182,000 | +193.5% | 42,114 | +9.7% | 0.00% | +100.0% |
| Q2 2017 | $62,000 | -29.5% | 38,380 | -19.5% | 0.00% | 0.0% |
| Q1 2017 | $88,000 | -2.2% | 47,654 | -18.1% | 0.00% | 0.0% |
| Q4 2016 | $90,000 | -72.3% | 58,189 | +31.5% | 0.00% | -80.0% |
| Q3 2016 | $325,000 | +17.3% | 44,251 | -15.0% | 0.01% | +25.0% |
| Q2 2016 | $277,000 | – | 52,038 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Western Financial Corp/CA | 820,320 | $33,272,179 | 21.56% |
| Aquilo Capital Management, LLC | 1,103,515 | $44,758,568 | 16.81% |
| M28 Capital Management LP | 143,900 | $5,836,584 | 5.56% |
| WEALTH EFFECTS LLC | 155,620 | $6,311,951 | 3.60% |
| Evolutionary Tree Capital Management, LLC | 92,095 | $3,735,373 | 3.59% |
| Privium Fund Management B.V. | 221,015 | $8,867,122 | 3.36% |
| JOHNSON & JOHNSON | 247,598 | $10,043 | 2.92% |
| COMMODORE CAPITAL LP | 462,111 | $18,743 | 2.82% |
| Avidity Partners Management LP | 1,375,000 | $55,770,000 | 1.21% |
| Capital Impact Advisors, LLC | 26,853 | $1,089,158 | 1.06% |